Wednesday 27 August 2008

LiveDaily Weekend Podcast, August 15: BB King, The Cheetah Girls, Delerium and more

This week's LiveDaily Weekend podcast features tour, ticketing and music news about BB King, The Cheetah Girls [ ], Delerium [ ], Jason Aldean [ ], Death Cab for Cutie [ ], Joan Osborne [ ], Rachael Yamagata [ ], Gym Class Heroes [ ], Eagles [ ], Coldplay [ ], Weezer, Carrie Underwood, Sugarland, Michael Buble, ZZ Top, Jackson Browne, Britney Spears, Isaac Hayes, Jonas Brothers, New Kids on the Block, David Sanborn, The Bug, Pop Evil, Miley Cyrus, Kid Rock and Lil Wayne.



story_top_holder>



mp3 versionSubscribe at iTunes


Listen now:



right_content player>








More info

Sunday 17 August 2008

U.S. NCI Starts Enrolment In Phase 2 Systemic Melanoma Clinical Trial With REOLYSIN(R)

�Oncolytics Biotech Inc.
("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced that the U.S.
National Cancer Institute (NCI), part of the National Institutes of Health,
has started enrollment in a Phase 2 clinical trial for patients with
metastatic melanoma victimization systemic administration of REOLYSIN(R),
Oncolytics' proprietary formulation of the human reovirus. The trial is
being carried out by the Mayo Phase 2 Consortium under the NCI's Clinical
Trials Agreement with Oncolytics, spell Oncolytics volition provide clinical
supplies of REOLYSIN(R). The Principal Investigator is Dr. Evanthia Galanis
of the Mayo Clinic Cancer Center.



The primary objectives of the study are to assess the antitumour
personal effects of REOLYSIN(R) in patients with metastatic malignant melanoma, as
easily as the safety profile of REOLYSIN(R). Secondary objectives include
assessment of progression free survival and overall survival.



Patients will receive systemic presidential term of REOLYSIN(R) at a dose
of 3x10(10) TCID(50) per day on days 15 of each 28 day cycle, and patients
may receive up to 12 cycles of treatment. The trial is expected to enroll
up to 47 patients with metastatic malignant melanoma.



Approximately 60,000 people are diagnosed with malignant melanoma in the U.S.
every year.

About Oncolytics Biotech Inc.



Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical programme includes a variety of Phase I/II and Phase II
human trials victimization REOLYSIN(R), its proprietary conceptualisation of the human
reovirus, alone and in combination with radiation or chemotherapy. For
further information around Oncolytics, please visit
hypertext transfer protocol://www.oncolyticsbiotech.com



This press release contains innovative statements, within the
substance of Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements, including the Company's expectations related to
the U.S. NCI Phase 2 systemic administration clinical trial for patients
with metastatic malignant melanoma, and the Company's belief as to the potential difference of
REOLYSIN(R) as a cancer therapeutic, involve known and obscure risks and
uncertainties, which could causal agent the Company's actual results to differ
materially from those in the forward-looking statements. Such risks and
uncertainties admit, among others, the accessibility of cash in hand and
resources to engage research and development projects, the efficaciousness of
REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside
a controlled quiz, the success and well timed completion of clinical studies
and trials, the Company's ability to successfully commercialize
REOLYSIN(R), uncertainties related to the research and development of
pharmaceuticals and uncertainties related to the regulatory process.
Investors should refer the Company's quarterly and annual filings with
the Canadian and U.S. securities commissions for additional entropy on
risks and uncertainties relating to the ahead looking statements.
Investors ar cautioned against placing undue reliance on forward-looking
statements. The Company does not undertake to update these forward-looking
statements.


Oncolytics Biotech Inc.
http://www.oncolyticsbiotech.com



More info

Thursday 7 August 2008

New York gospel singer Timothy Wright is still in critical condition










NEW YORK - A Grammy-nominated gospel singer from New York City remains in critical

Monday 30 June 2008

Deviated Presence

Deviated Presence   
Artist: Deviated Presence

   Genre(s): 
Metal: Death,Black
   



Discography:


Falls Passage   
 Falls Passage

   Year: 2004   
Tracks: 9




 






Wednesday 25 June 2008

Monolith

Monolith   
Artist: Monolith

   Genre(s): 
Other
   



Discography:


One Nation Under Metal   
 One Nation Under Metal

   Year: 2003   
Tracks: 11




Formed as an underground collective that delineated a collaboration between Toronto rap music crews Lyrical Coalition and The Horde, Monolith was born in 1994 with a line up that averages over 15 members. However, with each member busy with their possess solo projects and production deals, Monolith's number one official acquittance The Long Awaited EP wouldn't hit the streets until 1998, thanks to their own One Rock Records. The followup single "Bye D'Plenty"/"At The T.O.P." single came out that like yr without whatsoever aid from the euphony industry suits.





Led Zeppelin - Plant Lands First Americana Awards Nominations

Wednesday 18 June 2008

The Prophecy

The Prophecy   
Artist: The Prophecy

   Genre(s): 
Metal: Death,Black
   



Discography:


Ashes   
 Ashes

   Year: 2003   
Tracks: 6


To End All Hope   
 To End All Hope

   Year: 2002   
Tracks: 3




 





Fight Club: Lily Allen v Perez Hilton

Monday 16 June 2008

Barack Obama - Candidates Reject Town Hall Invite From Abc



John McCain and Barack Obama have each rejected an offer by New York Mayor
Michael Bloomberg and ABC News to appear in a general-election town hall that
would be hosted by Diane Sawyer. The two presidential candidates said that,
while they welcomed the town-hall format, they did not want it limited to one
TV network. McCain spokesman Tucker Bounds said, "Both campaigns agree the town
hall meetings will be open to the press but not sponsored or moderated by the
press."






09/06/2008





See Also